For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Tafamidis and the formulated version represents a true change. These novel therapies preserve the transthyretin protein, preventing its harmful build-up and alleviating the impact o